AVI BioPharma (AVII) to Present Prelim Safety Data for AVI-4658 At Action Duchennew Conference

October 22, 2009 10:09 AM EDT

AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it will present updated preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of AVI-4658 in patients with Duchenne muscular dystrophy (DMD) at the 7th Annual Action Duchenne Conference taking place Oct. 23-24 in London, UK.

Data to be presented at the conference will include updated safety information from the four patients being dosed in the penultimate dose cohort (10 mg/kg). In each cohort, including the final cohort of 20 mg/kg, data for the clinical effects of the treatment will be collected for 26 weeks from first dose.

Previously announced results from the ongoing Phase 1b/2 systemic trial have demonstrated that AVI-4658 has been well tolerated in patients with DMD in the first two completed cohorts (0.5 mg/kg and 1.0 mg/kg) and two ongoing cohorts (2.0 mg/kg and 4.0 mg/kg). There have been no drug-related safety issues identified.

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?